EGFR and glioblastoma: NOTCH1 substitutions showed a trend towards improved progression-free survival (PFS) (HR = 0.55 [0.30; 1.01], P = .054).<h4>Conclusion</h4>We identified new prognostic markers in GBM, showing for the first time that EGFR substitutions improve OS.